#United States #CAR-T therapy #ScaleReady #St. Paul #March Biosciences

ScaleReady Grants Support Advancements in CAR-T Therapies

In a significant move for cancer treatment innovation, ScaleReady has announced that March Biosciences has been awarded a $200,000 G-Rex® Grant, aimed at enhancing the manufacturing processes for a groundbreaking CAR-T cell therapy, MB-105. This collaborative effort, which includes expertise from Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, focuses on developing an autologous CAR-T cell therapy that specifically targets CD5 to treat patients suffering from various T-cell lymphomas.

Importance of Scaling Manufacturing

The potential of CAR-T therapies has revolutionized cancer treatment. As clinical trials progress, ensuring the scalability and efficiency of production becomes critical. According to Dr. Maksim Mamonkin, Chief Scientific Officer at March Biosciences, "This grant enables us to further develop a robust cGMP process utilizing the G-Rex bioreactor, simplifying and reducing costs associated with autologous CAR-T product manufacturing."

This scalable approach not only addresses current production challenges but also aims to streamline the path to effective commercialization of MB-105, which has recently gained orphan drug designation from the FDA for treating relapsed/refractory T-cell lymphomas. The unique therapy is designed to selectively target malignant CD5-positive T-cells while preserving normal cell function, which dramatically improves the safety and efficacy profile of CAR-T therapies.

Collaborative Efforts Towards Innovation

John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, reflects on the collaboration: "We are pleased to assist March Biosciences in overcoming scalability and efficiency barriers in autologous CAR-T manufacturing. Our expertise coupled with this grant will facilitate a nimble production process for MB-105, keeping patient needs at the forefront."

The grant supports the implementation of a G-Rex-centric, fully integrated manufacturing process, aiming to refine the GMP production of MB-105 and other innovations in the research pipeline. March Biosciences' move towards advanced manufacturing methods indicates their commitment to addressing unmet needs in cancer therapies.

Advancements in Cancer Treatment

MB-105 is under development for various CD5+ hematologic malignancies including T-cell lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and other similar conditions. As the Phase 2 clinical trial progresses, the focus will be on enrolling patients with specific lymphomas that have shown resistance to existing treatments.

The G-Rex Grant Program is pivotal in the field of cell and gene-modified cell therapy (CGT), and ScaleReady has committed substantial resources to continue fostering innovation in this domain. Since its launch, nearly 200 grants have been awarded, and the program has expanded due to an influx of funding aimed at supporting the development of advanced therapies.

As CGT research surges forward, the collaboration between ScaleReady, March Biosciences, and its partners exemplifies a collective effort to not only advance scientific understanding but also to bring effective therapies to market more efficiently. With millions of dollars in new funding and a growing consortium of expert partners, the landscape for CAR-T therapies is set for dynamic evolution.

For more information about the G-Rex® Grant Program, interested parties can reach out through ScaleReady's contact channels.

About ScaleReady

ScaleReady is at the forefront of cell and gene-modified cell therapy (CGT), offering a G-Rex-centric manufacturing platform designed for scalable and cost-effective drug development. It serves a vast network of over 800 organizations, responsible for a significant portion of CGT clinical trials.

About March Biosciences

March Biosciences, headquartered in Houston, emerged from prestigious institutions focused on addressing difficult cancers that resist current immunotherapies. With significant funding and a dedicated mission, March is poised to impact the oncology field substantially.

For the most current updates on this collaboration and ongoing trials, stay tuned to trusted medical news outlets as this significant advancement in CAR-T technology progresses.